Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

Vascular endothelial growth factor (VEGF) inhibitor medications such as ranibizumab, pegaptanib and bevacizumab are in use for the treatment of neovascular age-related macular degeneration (AMD) and other retinal conditions, although only ranibizumab and pegaptanib are approved for these conditions....

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Peter K., Cruess, Alan F., Bogaert, Peter, Khunti, Kamlesh, Kelly, Simon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490068/
https://www.ncbi.nlm.nih.gov/pubmed/23011000
http://dx.doi.org/10.1007/s00417-012-2123-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490068/
https://www.ncbi.nlm.nih.gov/pubmed/23011000
http://dx.doi.org/10.1007/s00417-012-2123-4

Ejemplares similares